DK0805683T3 - 5-fluor-2',3'-umættet-pyrimidinnukleosider - Google Patents

5-fluor-2',3'-umættet-pyrimidinnukleosider

Info

Publication number
DK0805683T3
DK0805683T3 DK96902772T DK96902772T DK0805683T3 DK 0805683 T3 DK0805683 T3 DK 0805683T3 DK 96902772 T DK96902772 T DK 96902772T DK 96902772 T DK96902772 T DK 96902772T DK 0805683 T3 DK0805683 T3 DK 0805683T3
Authority
DK
Denmark
Prior art keywords
pharmaceutically acceptable
fluoro
pyrimidine nucleosides
fluoroü
carboxamido
Prior art date
Application number
DK96902772T
Other languages
Danish (da)
English (en)
Inventor
Raymond F Schinazi
Dennis C Liotta
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of DK0805683T3 publication Critical patent/DK0805683T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK96902772T 1995-01-27 1996-01-29 5-fluor-2',3'-umættet-pyrimidinnukleosider DK0805683T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/379,276 US5703058A (en) 1995-01-27 1995-01-27 Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent

Publications (1)

Publication Number Publication Date
DK0805683T3 true DK0805683T3 (da) 2006-05-22

Family

ID=23496579

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96902772T DK0805683T3 (da) 1995-01-27 1996-01-29 5-fluor-2',3'-umættet-pyrimidinnukleosider

Country Status (10)

Country Link
US (6) US5703058A (fr)
EP (2) EP0805683B1 (fr)
JP (3) JPH10512887A (fr)
AT (1) ATE314077T1 (fr)
AU (1) AU717580B2 (fr)
CA (1) CA2211612C (fr)
DE (1) DE69635656T2 (fr)
DK (1) DK0805683T3 (fr)
ES (1) ES2255710T3 (fr)
WO (1) WO1996022778A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) * 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) * 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) * 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
EP1754710A3 (fr) * 1998-02-25 2007-12-19 Emory University 2'-Fluoronucleosides
DK1058686T3 (da) * 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider
KR100886653B1 (ko) 1998-02-25 2009-03-04 에모리 유니버시티 2'-플루오로뉴클레오사이드
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (fr) * 1998-05-29 1999-12-02 Maki Arai Therapie combinee pour le traitement des infections dues au vif
JP2002518452A (ja) * 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用
ID29471A (id) * 1998-11-02 2001-08-30 Triangle Pharmaceuticals Inc Terapi kombinasi untuk mengobati virus hepatitis b
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
CN1216893C (zh) 1998-11-05 2005-08-31 法国国家科学研究中心 具有抗乙型肝炎病毒活性的核苷
EP1731155A3 (fr) * 1999-01-22 2007-02-21 Emory University Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine pour l'utilisation dans le traitement d'une infection par le hiv
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
MXPA01007359A (es) * 1999-01-22 2003-09-22 Univ Emory Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih.
EP1173161A2 (fr) 1999-02-12 2002-01-23 G.D. SEARLE & CO. Composes glucamine destines au traitement d'infections dues au virus de l'hepatite
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
WO2001014345A1 (fr) * 1999-08-20 2001-03-01 The Research Foundation Of State University Of New York Derives 5-propynylpyrimidine utilises comme inhibiteurs d'enzyme cytotoxique
KR100325682B1 (ko) * 1999-10-25 2002-02-25 김태성 2',3'-디디하이드로-2',3'-디데옥시시티딘 유도체의 제조방법
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1411954B1 (fr) 2000-10-18 2010-12-15 Pharmasset, Inc. Nucleosides modifies pour traiter des infections virales et une proliferation cellulaire anormale
MXPA03007853A (es) 2001-03-01 2004-05-24 Pharmasset Ltd Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.
US6914052B2 (en) 2001-03-15 2005-07-05 The Trustees Of Boston College Selective anti-viral nucleoside chain terminators
AU2002322325A1 (en) * 2001-06-22 2003-01-08 Emory University Beta-2'-or 3'-halonucleosides
AU2002355739A1 (en) 2001-07-30 2003-02-17 University Of Southern California Preparation and use of alpha-keto phosphonates
AU2002365234B2 (en) * 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
MXPA04009986A (es) * 2002-04-12 2005-08-16 Achillion Pharmaceuticals Inc Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
CN100536852C (zh) * 2002-07-15 2009-09-09 基利得科学公司 L-fmau在制备联合治疗乙型肝炎病毒感染的药物中的应用
WO2004043402A2 (fr) * 2002-11-12 2004-05-27 Pharmasset, Inc. Nucleosides modifies utilises comme agents antiviraux
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005055955A2 (fr) * 2003-12-09 2005-06-23 Pharmasset, Inc. PROCEDES DE DOSAGE DESTINES A UNE THERAPIE ANTIVIRALE A BASE DE ss-D-2',3'-DIDEOXY-2',3'-DIDEHYDRO-5-FLUOROCYTIDINE
US7741334B2 (en) * 2004-04-01 2010-06-22 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
US20060084628A1 (en) * 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
WO2006055754A1 (fr) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Procede visant a traiter l'infection a vih par l'administration combinee du tipranavir et du reverset
CA2636007A1 (fr) * 2006-01-13 2007-07-26 Wyeth 1h-indoles substitues par un groupe sulfonyle en tant que ligands pour les recepteurs de la 5-hydroxytryptamine
FR2907786B1 (fr) * 2006-10-27 2009-09-18 Univ Grenoble 1 Thionucleosides et applications pharmaceutiques
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2684061A1 (fr) * 2007-04-10 2008-10-16 Emory University Nouvelle deletion d'un codon de la transcriptase inverse de vih-1 et son utilisation dans la gestion et le traitement des infections a vih
EP2207553A4 (fr) * 2007-10-02 2010-12-29 Univ Emory Combinaisons puissantes de zidovudine et médicaments qui réalisent une sélection de la mutation k65r dans la polymérase du vih
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075554A1 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthèse de nucléosides de type purine
PA8855701A1 (es) * 2008-12-23 2010-07-27 Análogos de nucleósidos
EA019341B1 (ru) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011035120A2 (fr) * 2009-09-17 2011-03-24 Gk Ventures, L.L.C. Composition thérapeutique pour traiter des lésions provoquées par le virus herpès simplex
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
EP2646453A1 (fr) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Composés
CN104244945B (zh) 2011-09-16 2016-08-31 吉利德制药有限责任公司 用于治疗hcv的方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
PT3650014T (pt) 2013-08-27 2021-12-27 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US400137A (en) * 1889-03-26 Louis steinberger
US521161A (en) * 1894-06-12 Broom-head
US2248776A (en) * 1938-07-28 1941-07-08 Bell Telephone Labor Inc Wave filter
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3346561A (en) * 1965-10-24 1967-10-10 Merck & Co Inc Pyrimidine 3-deoxynucleosides
US3553192A (en) * 1968-07-15 1971-01-05 Robugen Gmbh Substituted (2'-deoxyribosyl) uracil compounds, compositions containing same and process of making and using same
US3817982A (en) 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (fr) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
JPS62242624A (ja) * 1986-04-15 1987-10-23 Asahi Glass Co Ltd 抗腫瘍剤
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
DD279407A1 (de) * 1986-07-24 1990-06-06 Akad Wissenschaften Ddr Verfahren zur herstellung eines mittels gegen aids
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
SE469823B (sv) 1987-02-23 1993-09-27 Univ Western Australia Ledmekanism för robotarmar
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
DE3850571T2 (de) * 1987-03-24 1994-10-27 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
US5215970A (en) * 1987-04-16 1993-06-01 Medivir Ab Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
JPH02152976A (ja) * 1988-05-06 1990-06-12 Bristol Myers Co ２´，３´―ジデヒドロ―２´，３´―ジデオキシヌクレオシドのプロドラッグ
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
EP0355031A3 (fr) 1988-08-17 1990-12-27 MATTHES, Eckart, Dr. Nucléosides pyrimidiniques substitués, leur procédé de préparation et médicaments les contenant
DE10299039I1 (de) * 1988-12-19 2003-02-20 Wellcome Found Antivirale Pyrimidin- und Purinverbindungen Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Praeparte
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
JP3160291B2 (ja) * 1989-02-08 2001-04-25 バイオケム ファーマ インコーポレイテッド 抗ウイルス特性を有する置換１，３‐オキサチオランを調製する方法
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
JPH05501404A (ja) 1989-11-06 1993-03-18 ニユコメド・アクシエセルカペト ヌクレオシド誘導体
CA2032259A1 (fr) * 1989-12-18 1991-06-19 Wayne J. Thompson Inhibiteurs de la protease du vih utiles dans le traitement du sida
DE69031271T2 (de) * 1989-12-20 1998-02-26 Biotech Australia Pty Ltd Varianten von pai-2
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
US5241069A (en) * 1990-04-06 1993-08-31 Glaxo Inc. Carbonate intermediates for the synthesis of purine substituted cyclopentene derivatives
US5128458A (en) * 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
WO1991019727A1 (fr) * 1990-06-19 1991-12-26 Sloan-Kettering Institute For Cancer Research 5-hydrogenophosphonates et 5'-methylphosphonates de nucleosides modifies du sucre, compositions et utilisations de ces produits pour traiter des infections virales
EP0465297B1 (fr) * 1990-07-04 1996-01-31 Merrell Dow Pharmaceuticals Inc. Dérivés d'acides 9-purinyl phosphoniques
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
IT1246983B (it) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DK0574487T3 (da) * 1991-03-06 2002-10-14 Univ Emory Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
JP3042073B2 (ja) 1991-06-19 2000-05-15 味の素株式会社 ヌクレオシド誘導体とその製造方法
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US5233041A (en) * 1991-10-07 1993-08-03 Glaxo Group Limited Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone from a 2,3-unsaturated-1-cyclopentanylpurinone
US5232300A (en) * 1992-01-17 1993-08-03 Paco Pharmaceutical Services, Inc. Brush decontamination kit
US5432165A (en) * 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
US5271186A (en) * 1992-05-13 1993-12-21 Perneczky George C Tandem pneumatic/hydraulic reciprocating cylinder with integral oil reservoir
EP0639971B1 (fr) * 1992-05-13 1999-09-22 The Wellcome Foundation Limited Combinaisons therapeutiques
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
EP0626970A1 (fr) * 1992-12-18 1994-12-07 The University Of Alberta Nucleosides de dihydropyrimidine a proprietes antivirales
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5329008A (en) * 1993-04-07 1994-07-12 Glaxo Inc. Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone
CA2163456C (fr) * 1993-05-21 2009-06-23 Franco Lori Nouvelle methode pour bloquer la replication de virus dependant de transcriptases inverses grace a des inhibiteurs de la synthese de desoxynucleotides
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
EP0631783A1 (fr) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Combinaisons antivirales de 2',3'-didéoxy-ribonucléosides avec des dérivés 5-substitués du 6-benzyl-1-éthoxyméthyl-uracile
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
AU7954694A (en) * 1993-09-10 1995-03-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis b virus activity
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
WO1995018137A1 (fr) * 1993-12-30 1995-07-06 Genta Incorporated Procedes ameliores de purification d'oligomeres
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
DK1058686T3 (da) 1998-02-25 2007-03-05 Univ Emory 2'-fluornukleosider

Also Published As

Publication number Publication date
ATE314077T1 (de) 2006-01-15
JP2007246540A (ja) 2007-09-27
US6680303B2 (en) 2004-01-20
AU717580B2 (en) 2000-03-30
US20020198173A1 (en) 2002-12-26
US5905070A (en) 1999-05-18
JPH10512887A (ja) 1998-12-08
CA2211612A1 (fr) 1996-08-01
AU4705696A (en) 1996-08-14
US7419966B2 (en) 2008-09-02
WO1996022778A1 (fr) 1996-08-01
US20040167140A1 (en) 2004-08-26
ES2255710T3 (es) 2006-07-01
US5703058A (en) 1997-12-30
EP0805683B1 (fr) 2005-12-28
CA2211612C (fr) 2006-08-15
DE69635656T2 (de) 2006-09-21
US6232300B1 (en) 2001-05-15
JP2005325128A (ja) 2005-11-24
EP1361227A2 (fr) 2003-11-12
EP0805683A4 (fr) 1999-09-01
DE69635656D1 (de) 2006-02-02
EP1361227A3 (fr) 2004-03-03
EP0805683A1 (fr) 1997-11-12
US20080293668A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
ATE314077T1 (de) 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside
ATE165004T1 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
EP0199451A3 (en) Therapeutic nucleosides
NO963138D0 (no) L-Nukleosider for behandling av hepatit-B-virus og Epstein-bar-virus
WO1992014743A3 (fr) Activite antivirale et resolution de 2-hydroxymethyl-5-5-fluorocytosine-1-yl-1,3-oxathiolane
DK224286D0 (da) 2',3'-dideoxy-nucleosider
MY102693A (en) Antiviral nucleosides
EP1808434A3 (fr) Utilisation de 5-fluoro-2'-deoxy-3'-thiacytidine pour le traitement de l'hépatite B
AU4461189A (en) Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
NO904901L (no) N-substituerte derivater av 3r,4r-etyl-((1-metyl-1h-imidazol-5-yl)metyl) -2-pyrrolidinon.
ATE267198T1 (de) Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
NO921679L (no) Inhibitorer av purin-nukleosid-fosforylase
DK630589A (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
ATE111477T1 (de) 2'-halomethyliden, 2'-ethenyliden und 2'-ethynyl- adenosinderivate.
DK291390A (da) Terapeutiske anvendelser af 2',5'-oligoadenylatderivater
NO891835L (no) Prodrug-former av 2',3'-didehydro-2',3'-dideoksy-nukleosider.
AU2487688A (en) Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5- ethyluracil
MC2071A1 (fr) Procedes pour la preparation de derives de nucleosides antiviraux et de formulations pharmaceutiques les contenant
WO1988003804A3 (fr) Procede pour traiter des infections virales chez des humains, et compositions a cet effet
FI935042A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 2'-etenylideenisytidiini-, uridiini- ja guanosiinijohdannaisten valmistamiseksi
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b